Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions reflect on specific findings from the article, such as the notable reduction in major cardiovascular events in patients with a target systolic blood pressure of less than 120 mm Hg compared to 140 mm Hg. Phrases like 'old blood pressure targets are no longer acceptable' and 'evidence continues to mount' convey a sense of urgency and transformation in how these conditions might be treated moving forward. The tone across the posts is generally positive and supportive, showcasing a forward-thinking attitude toward the implications of this research.
The majority of discussions indicate strong support for the findings presented in the publication, highlighting a consensus on the benefits of intensive blood pressure control.
Participants express high interest in the study, frequently referencing its implications for current medical practices.
While many posts summarize findings, a few delve into specific outcomes and potential changes to clinical guidelines, indicating moderate engagement.
There is a widespread belief that these findings could significantly alter treatment protocols for managing blood pressure in diabetic patients.
Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure target of 120. New study published in the NEJM titled: "Intensive Blood-Pressure Control in Patients with Type 2 Diabetes" The BPROAD study determined suitable https://t.co/bkAfz1siFe
In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major CV events vs standard <140 mm Hg. Results of a RCT (DOI: 10.1056/NEJMoa2412006) More intensive BP control = better outcomes. Summary
BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120 mm Hg than w/ standard treatment targeting SBP < 140 mm Hg #Nephpearls #NephJC #VisualAbstract by @KajareeG
In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd #MedSky #CardioSky
Original Article: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD trial) https://t.co/HrGBjmBr7A Editorial: BPROAD — End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes? https://t.co/VG872CvAGg #Cardiology https://t.co/gWWvrrnj3N
This video explores how climate change impacts marine ecosystems. We'll dive into the changes in ocean temperature, acidity, and effects on biodiversity, highlighting recent research findings and their implications for…
This week, John Mandrola MD discusses the latest hypertension guidelines targeting systolic blood pressure for type 2 diabetes patients, highlighting intensive treatment's impact on cardiovascular events. Also covered…
RT @EricTopol: New @NEJM and #AHA24 A large randomized trial in people with Type 2 diabetes showed intensive BP lowering (systolic < 120 m…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
RT @_Anesthesiology: Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Med…
Read a summary of "Intensive blood-pressure control in patients with type 2 diabetes," in the August 2025 Science, Medicine, and the Anesthesiologist: https://t.co/JavW4BESFk https://t.co/ZHxX1ScyZT
RT @TGijonConde: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine @SEHLELHA140_90 @AMARE…
RT @TGijonConde: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine @SEHLELHA140_90 @AMARE…
RT @TGijonConde: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine @SEHLELHA140_90 @AMARE…
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine @SEHLELHA140_90 @AMAREVA_Madrid https://t.co/I7IzdIopMd https://t.co/qylnzfTfeB
"Intensive Blood-Pressure Control in Patients with Type 2 Diabetes" #Health #Healthcare #ElderCare #MedSky
RT @irjpnmEqqEUJraX: BPROAD試験 NEJM2024 中国2型DM合併高血圧患者12,821例。標準降圧(目標SBP 140)に比し厳格降圧(120mmHg)で MACEのHR 0.79へ低下、主に脳卒中の減少。CKD発症・進行に有意差なし。 https…
Full text links https://t.co/kQ0m2ICP5s https://t.co/4WrBzp2qwf
Acceso bibliografía @PubMedOnline Intensive Blood-Pressure Control in Patients with Type 2 Diabetes Yufang Bi et al. N Engl J Med. 2025. https://t.co/QHzVIhFYlF https://t.co/HNCbQllxLb
NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/jewjNRvMEZ
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
RT @BradStanfieldMD: Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure…
Nach 4,2 Jahren zeigte sich: Die intensiv behandelte Gruppe hatte signifikant weniger Herzinfarkte, Schlaganfälle und Todesfälle durch Herz-Kreislauf-Erkrankungen – bei vergleichbarem Sicherheitsprofil. https://t.co/Y43R8ig7hH https://t.co/U9KVP77MId
Eine aktuelle Studie im New England Journal of Medicine („Intensive Blood-Pressure Control in Patients with Type 2 Diabetes“) zeigt: https://t.co/rpznJz1lDe
Study link: https://t.co/TPH8wCTa45
Old blood pressure targets are no longer acceptable. Evidence continues to mount for a lower systolic blood pressure target of 120. New study published in the NEJM titled: "Intensive Blood-Pressure Control in Patients with Type 2 Diabetes" The BPROAD study determined suitable https://t.co/bkAfz1siFe
8/
16) BPROAD: Strong #CV benefit, no renal harm
16) BPROAD: Strong #CV benefit, no renal harm
「2型糖尿病でSBP<120 vs SBP<140とすると、前者は主要な心血管イベントの発生率を有意に低下/一方で症候性低血圧や高カリウム血症のリスクは増加」 外来でついまぁちょい高いっすけどもう少し様子見てみましょうか〜とか言っちゃうことあるけど, もっと厳格にせないかんかなぁhttps://t.co/QNQxIYoGez
RT @EricTopol: New @NEJM and #AHA24 A large randomized trial in people with Type 2 diabetes showed intensive BP lowering (systolic < 120 m…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
RT @AMAREVA_Madrid: Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co…
Nuevo comentario del ensayo clínico BPROAD sobre de la Dra. Adriana Puente García https://t.co/V5WC8CdxWv https://t.co/at2xZBSLP6
RT @HOATRAN82820145: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes https://t.co/BEUMFiGfMF
Intensive blood-pressure control in patients with type 2 diabetes – Study finds the incidence of major cardiovascular events was significantly ⬇️ w/ treatment targeting a systolic blood pressure <120 mm Hg vs. standard treatment targeting a BP < 140 mm Hg. https://t.co/wQ2KOl0k4S https://t.co/zQYYBHAIXV
RT @mmacia25: Estudio que confirma la necesidad de ser mas exigente en el control de la HTA en pacientes con DM2. Intensive Blood-Pressure…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @Tak0123: 今週のNEJMに2型糖尿病患者の降圧目標に関するRCTが 収縮期血圧を120未満に厳格に管理すると、140未満に抑える標準治療と比べて、心血管イベント（脳卒中、心筋梗塞、心不全、心血管死）の複合アウトカムが有意に低下した（1.65 vs 2.09/1…
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/uzXM0p2Nsi
#DM2
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/A7ObUaaP1C
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/j4dJy7kx63
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
RT @docmaltese: In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major…
In adults with type 2 diabetes & increased risk of CV disease, targeting systolic BP <120 mmHg significantly reduces major CV events vs standard <140 mm Hg. Results of a RCT (DOI: 10.1056/NEJMoa2412006) More intensive BP control = better outcomes. Summary
Intensive BP control in 50+ yr olds with type 2 diabetes targets <120 mmHg, compared to standard <140 mmHg. Study at 145 sites in China! PMID:39555827, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2412006 #Medsky #Pharmsky #RNA #ASHG #ESHG
Intensive blood pressure control in type 2 diabetes patients significantly reduced major cardiovascular events compared to standard treatment. by Bi Y, Li M (...) Wang W et 43 al. in N Engl J Med #MedSky
Intensive blood pressure control in type 2 diabetes patients significantly reduced major cardiovascular events compared to standard treatment. by Bi Y, Li M (...) Wang W et 43 al. in N Engl J Med https://t.co/5654RZ8Gex #MedX #MedResearch
Intensive BP control in 50+ yr olds with type 2 diabetes targets <120 mmHg, compared to standard <140 mmHg. Study at 145 sites in China! PMID:39555827, N Engl J Med 2025, @NEJM https://t.co/zHL2oXEfIv #AI #Pharma #BioMed #RNA #ASHG #ESHG
Control intensivo de la presión arterial en pacientes con diabetes tipo 2 https://t.co/dpu55YVHVi PMID 39555827
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: Original Article: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD trial) https://t.co/HrGBjmBr7A Edit…
RT @NEJM: Original Article: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD trial) https://t.co/HrGBjmBr7A Edit…
RT @NEJM: Original Article: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD trial) https://t.co/HrGBjmBr7A Edit…
RT @NEJM: Original Article: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD trial) https://t.co/HrGBjmBr7A Edit…
Original Article: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD trial) https://t.co/HrGBjmBr7A Editorial: BPROAD — End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes? https://t.co/VG872CvAGg #Cardiology https://t.co/gWWvrrnj3N
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd #MedSky #CardioSky
RT @YHC_Shibuya: 【DrゆみのWeekly Journal Scan】 ＊糖尿病患者の血圧管理 from NEJM＊ https://t.co/pWINe3x1ou 2型糖尿病患者における収縮期血圧の最適管理目標を検討する多施設無作為化比較試験で。中国国内の14…
RT @YHC_Shibuya: 【DrゆみのWeekly Journal Scan】 ＊糖尿病患者の血圧管理 from NEJM＊ https://t.co/pWINe3x1ou 2型糖尿病患者における収縮期血圧の最適管理目標を検討する多施設無作為化比較試験で。中国国内の14…
【DrゆみのWeekly Journal Scan】 ＊糖尿病患者の血圧管理 from NEJM＊ https://t.co/pWINe3x1ou 2型糖尿病患者における収縮期血圧の最適管理目標を検討する多施設無作為化比較試験で。中国国内の145施設で50歳以上の患者12,821名を、目標血圧120 mmHg未満の強化治療群と140
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/O9Sip1v8ia
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
درمان فشرده برای کاهش فشار خون سیستولیک به کمتر از ۱۲۰ میلیمتر جیوه، در بیماران مبتلا به دیابت نوع ۲ بهطور معنیداری خطر بروز حوادث قلبی–عروقی عمده را در مقایسه با درمان استاندارد (هدف کمتر از ۱۴۰ میلیمتر جیوه) کاهش میده! https://t.co/mRmzNMGxKM
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @NEJM: In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-p…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/r3lB7zTIK0
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes https://t.co/BEUMFiGfMF
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/x2rdqjvxss
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
RT @mmacia25: Estudio que confirma la necesidad de ser mas exigente en el control de la HTA en pacientes con DM2. Intensive Blood-Pressure…
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/PFpdABasrz
RT @MondaEmanuele: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes @NEJM https://t.co/T81xDopUFL https://t.co/AUqmmzBf…
"Intensive Blood-Pressure Control in Patients with Type 2 Diabetes." Publié ce jour dans le @nejm.org. #MedSky #Hypertension www.nejm.org/doi/full/10....
BPROAD試験 https://t.co/5TDZNe7KCT https://t.co/JLre17YUAh
RT @cardio_tu: 2 min cardiology（臨床、担当：山田祐資） Intensive Blood-Pressure Control in Patients with Type 2 Diabetes Y Bi et al. NEJM Nov 16, 2…
RT @DRKAMALAYOUB: خفض الضغط الشرياني الانقباضي من ١٤٠ الى ١٢٠ ملم زئبقي لدى الاشخاص المصابين بداء السكري من النوع الثاني ادى الى خفض احتمال…
خفض الضغط الشرياني الانقباضي من ١٤٠ الى ١٢٠ ملم زئبقي لدى الاشخاص المصابين بداء السكري من النوع الثاني ادى الى خفض احتمال الاصابة بانسداد شرايين القلب بنسبة ٢١٪ . مما يؤكد ضرورة خفض الضغط الى مستويات طبيعية كل الوقت لدى هذه الفئة من المرضى. https://t.co/2cV9l0UsqS
2 min cardiology（臨床、担当：山田祐資） Intensive Blood-Pressure Control in Patients with Type 2 Diabetes Y Bi et al. NEJM Nov 16, 2024 https://t.co/bNaCVPF3hr 2型糖尿病における厳格な血糖コントロール(収縮期血圧 <120mmHg vs <140mmHg)の有効性を示したRCT。 →
糖尿病でも厳格降圧 https://t.co/sk6IT54EMl
RT @redGDPS: Acceso a publicación en
RT @redGDPS: Full Text links Control intensivo de la presión arterial en pacientes con diabetes tipo 2 | New England Journal of Medicine ht…
Full Text links Control intensivo de la presión arterial en pacientes con diabetes tipo 2 | New England Journal of Medicine https://t.co/AcdI4KikV5
Acceso a publicación en
【BPROAD試験】読んだ! ★50歳以上のT2DM+高血圧+CVDリスクがある12821人 ★sBP120mmHg未満目標vs140mmHg未満目標 ★心血管イベントは1.65/100人年vs2.09/100人年でHR0.79 ★SPRINT試験同様、血圧はきっちり下げるべきかも …個人的にCKD患者はあんまりいなかったのが残念
2/10 What'd I miss? ❗⏫BP
2/10 What'd I miss? ❗⏫BP more
The debate of strict versus lenient blood pressure control continues with more data supporting the former just published. Read the full text of the BROAD trial in #NEJM below. https://t.co/60bTFZvnLh
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
RT @edgarvlermamd: BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120…
BPROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120 mm Hg than w/ standard treatment targeting SBP < 140 mm Hg #Nephpearls #NephJC #VisualAbstract by @KajareeG
RT @edgarvlermamd: BROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120 m…
RT @edgarvlermamd: BROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120 m…
BROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120 mm Hg than w/ standard treatment targeting SBP < 140 mm Hg #Nephpearls #NephJC #VisualAbstract by @kajareeg.bsky.social
BROAD: Among patients w/ T2D, the incidence of MACE was significantly lower w/ intensive treatment targeting SBP < 120 mm Hg than w/ standard treatment targeting SBP < 140 mm Hg #Nephpearls #NephJC #VisualAbstract by @KajareeG
RT @CajinaCarmen: Intensive Blood-Pressure Control in Patients with Type 2 Diabetes - PubMed https://t.co/NCw6WLBRfq
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes - PubMed https://t.co/NCw6WLBRfq
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/KPbMsYqoam
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
Control intensivo de la presión arterial en pacientes con diabetes tipo 2 https://t.co/VGeriT3nDo PMID 39555827
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
Intensive blood-pressure control in type 2 diabetes patients significantly reduced major cardiovascular events compared to standard treatment. by Bi Y, Li M (...) Dong Q et 5 al. in N Engl J Med https://t.co/5654RZ9e45
【RCT】収縮期血圧が高く、心血管リスクが高い50歳以上の2型糖尿病患者での厳格な降圧（120mmHg未満）は、標準的な降圧（140mmHg未満）と比較して、非致死性脳卒中、非致死性心筋梗塞、心不全の治療または入院、心血管死亡の複合転帰リスクを減少させた。 #ペ読 https://t.co/tOmbkyIKOG
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes https://t.co/lzFjmNkeE8
Intensive Blood-Pressure Control in Patients with Type 2 #Diabetes www.nejm.org/doi/full/10.... Among patients with DM, the incidence of major CV events was significantly lower with intensive tx targeting a SBP <120 than with standard tx targeting a SBP of <140 mm Hg. #MedSky #PrimaryCare
RT @EARL_med_tw:
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes: @NEJM
So much evidence now that SBP targets should be lower than we used to think necessary. ACCORD in same pop wasn’t significant but smaller; SPRINT in people without diabetes similar results as here; also benefits for dementia (SPRINT MIND). #MedSky https://www.nejm.org/doi/full/10.1056/NEJMoa2412006
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes #BPROAD www.nejm.org/doi/full/10.... #NEJM #AHA24 #CardioSky #Hypertension #MedSky @ahascience.bsky.social @dramitkhera.bsky.social
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes www.nejm.org/doi/full/10....